Skip to content
Review

Targeting lipid peroxidation-derived aldehydes in Parkinson's Disease and ageing: Antioxidant investigations and mechanistic insights.

Oct 2026 · Ageing Research Reviews · pp. 103432 · 0 citations · 307 references
Medicine

Abstract

Oxidative stress and lipid peroxidation are increasingly recognized as age-related drivers of neurodegeneration, with Parkinson's disease (PD) representing a condition of heightened vulnerability. Among lipid peroxidation products, reactive aldehydes including 4-hydroxy-2-nonenal, malondialdehyde, acrolein, 4-hydroxy-2-hexenal, and crotonaldehyde have emerged not only as biomarkers of oxidative damage, but also as active mediators of neuronal dysfunction. Owing to their electrophilic nature, these aldehydes interact with nucleophilic residues, including cysteine, lysine, and histidine, forming covalent adducts that impair proteostasis, mitochondrial function, and redox signaling. Under physiological conditions, lipid peroxidation-derived aldehydes (LPDAs) are detoxified through glutathione-dependent conjugation and oxidoreductase-mediated metabolism. However, ageing progressively impairs these protective systems, promoting aldehyde accumulation and increasing dopaminergic vulnerability. We propose that PD may reflect, at least in part, an age-dependent impairment of aldehyde detoxification in addition to increased reactive oxygen species production. Although current experimental and clinical evidence supports the pathogenic relevance of some LPDAs in PD, antioxidant-based interventions have yielded inconsistent clinical outcomes. Within this framework, antioxidant strategies can be interpreted according to their functional impact on aldehyde burden. Approaches aimed at restoring glutathione homeostasis or activating Nrf2-dependent pathways may enhance endogenous detoxification systems and thereby support aldehyde clearance. More directly targeted approaches include strategies that enhance aldehyde metabolism, such as pharmacological activation of ALDH2. Overall, shifting the therapeutic focus from radical scavenging to the modulation of aldehyde burden through combined upstream and downstream interventions represents a promising but still underexplored avenue in PD and age-related neurodegenerative disorders that warrants further validation in clinical settings.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.